RECRUITING

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the progression of hepatobiliary damage in subjects with pediatric onset AILD. This study will involve collection of MRI-based data at the time of enrollment and at year 1 and 2 of follow up, and collection of clinical data for 10 years following enrollment. There is a strong possibility that MRI quantitative techniques may be more sensitive to disease progression than standard clinical and laboratory tests. To investigate predictivity of MRI based biomarkers, summary measures of MRCP/MREL from baseline, Year 1 and Year 2, e.g. change rate, maximum, and average will be calculated as predictors for Year 10 clinical outcomes. The same predictors will also be used to model native liver survival in a proportional hazard regression. Findings from this study may be used to assess disease progression and to predict complications and survival of liver disease patients.

Official Title

Longitudinal Study for the Assessment of MRI Based Biomarkers as a Predictors of Clinical Endpoints in Pediatric Onset Autoimmune Liver Disease

Quick Facts

Study Start:2017-02-20
Study Completion:2031-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03178630

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:6 Years to 23 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age 6-23 years old.
  2. 2. Established clinical diagnosis of AIH or PSC.
  1. 1. History of liver transplantation.
  2. 2. Chronic Hepatitis B or untreated hepatitis C virus infection.
  3. 3. Pregnancy.
  4. 4. Absolute contraindication for MRI (e.g. pacemaker, metallic implants, claustrophobia).
  5. 5. Diagnosis of cystic fibrosis or biliary atresia
  6. 6. Diagnosis of cardiac hepatopathy.
  7. 7. Diagnosis of Wilson's disease, Alpha-1 Antitrypsin deficiency, or Glycogen storage disease.
  8. 8. Skin conditions which could be aggravated by MREL (i.e. Epidermolysis bullosa).

Contacts and Locations

Study Contact

Alexander Miethke, MD
CONTACT
513-636-8948
alexander.miethke@cchmc.org
Cyd Castro Rojas, PhD
CONTACT
513-517-0580
cyd.castrorojas@cchmc.org

Principal Investigator

Alexander Miethke, MD
PRINCIPAL_INVESTIGATOR
Cincinnati Childrens Hospital Medical Center

Study Locations (Sites)

Cincinnati Children's Hospital and Medical Center
Cincinnati, Ohio, 45229
United States

Collaborators and Investigators

Sponsor: Children's Hospital Medical Center, Cincinnati

  • Alexander Miethke, MD, PRINCIPAL_INVESTIGATOR, Cincinnati Childrens Hospital Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-02-20
Study Completion Date2031-02

Study Record Updates

Study Start Date2017-02-20
Study Completion Date2031-02

Terms related to this study

Additional Relevant MeSH Terms

  • Autoimmune Liver Disease
  • Autoimmune Hepatitis
  • Primary Sclerosing Cholangitis